Amgen Offering Possible 8.34% Return Over the Next 31 Calendar Days

Amgen's most recent trend suggests a bullish bias. One trading opportunity on Amgen is a Bull Put Spread using a strike $110.00 short put and a strike $100.00 long put offers a potential 8.34% return on risk over the next 31 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $110.00 by expiration. The full premium credit of $0.77 would be kept by the premium seller. The risk of $9.23 would be incurred if the stock dropped below the $100.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Amgen is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Amgen is bullish.

The RSI indicator is at 48.37 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Amgen

4 Healthcare Stock Stories Waiting for Your Perusal
Wed, 20 Nov 2013 22:41:09 GMT
Wall St. Cheat Sheet – Analysis of Top healthcare Business News: 4 Healthcare Stock Stories Waiting for Your Perusal

Ahead of the Bell: Amgen's cholesterol drug
Wed, 20 Nov 2013 14:24:41 GMT

Ahead of the Bell: Amgen's cholesterol drug
Wed, 20 Nov 2013 14:24:41 GMT
AP – Amgen said Tuesday that an experimental drug reduced patients' “bad” cholesterol levels by half in a yearlong study. The company said patients who took the drug, called evolocumab, and standard …

Amgen Announces Evolocumab (AMG 145) Results From First 52-Week Study Of A PCSK9 Inhibitor To Reduce LDL Cholesterol
Tue, 19 Nov 2013 23:22:37 GMT
noodls – THOUSAND OAKS, Calif., Nov. 19, 2013 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced results from the Open Label Study of Long TERm Evaluation Against LDL-C (OSLER) trial, a long-term controlled 52-week …

Amgen cholesterol drug appears safe, cut LDL 52 pct at 1 year-study
Tue, 19 Nov 2013 23:15:43 GMT
Reuters – Amgen Inc's experimental heart medicine from a closely watched new class of drugs called PCSK9 inhibitors lowered “bad” LDL cholesterol 52 percent after one year with no major increase in serious adverse side effects compared with standard drugs, such as statins, according to data from a study. The clinical trial of the drug, evolocumab, marks the first data looking at 52 weeks of use for the new class of injectable biotech medicines seen as potentially the biggest advance in the field of cholesterol therapy in many years. Several companies are developing the drugs, which work by blocking a protein that prevents the liver from removing LDL cholesterol from blood. In addition to Amgen, Pfizer Inc and Regeneron Pharmaceuticals Inc in partnership with Sanofi are in advanced stages of testing PCSK9 inhibitors.

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.